Impact of GLP-1 Medications on Obesity-Related Cancer Risk
Global Obesity Statistics
In 2022, approximately 2.5 billion adults worldwide were classified as living with obesity. Research indicates that obesity is associated with an increased risk for various cancers.
Study Findings on GLP-1 Drugs
A recent study suggests that glucagon-like peptide-1 (GLP-1) medications, which are commonly used for weight loss, have minimal to no effect on the risk of developing obesity-related cancers. The study estimates that in the same year, around 890 million adults, or one in every eight individuals globally, were affected by obesity.
Health Risks Associated with Obesity
Obesity is linked to several adverse health conditions, including cardiovascular diseases, type 2 diabetes, and kidney disease. Furthermore, it has been associated with a higher likelihood of developing numerous types of cancers. These cancers encompass thyroid, pancreatic, breast, kidney, colorectal, esophageal, liver, gallbladder, ovarian, gastric, and endometrial cancers, along with multiple myeloma and meningioma, a tumor situated between the skull and spinal cord.
Publication Details
The findings of this study have been published in the journal *Annals of Internal Medicine*, contributing to the ongoing discussion about the effects of GLP-1 receptor agonist medications, such as Wegovy and Zepbound, on health outcomes related to obesity.